Temporin-SHa and Its Analogs as Potential Candidates for the Treatment of Helicobacter pylori

is one of the most prevalent pathogens colonizing 50% of the world's population and causing gastritis and gastric cancer. Even with triple and quadruple antibiotic therapies, shows increased prevalence of resistance to conventional antibiotics and treatment failure. Due to their pore-forming ac...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules (Basel, Switzerland) Switzerland), 2019-10, Vol.9 (10), p.598
Main Authors: Olleik, Hamza, Baydoun, Elias, Perrier, Josette, Hijazi, Akram, Raymond, Josette, Manzoni, Marine, Dupuis, Lucas, Pauleau, Ghislain, Goudard, Yvain, Villéon, Bruno de La, Goin, Géraldine, Sockeel, Philippe, Choudhary, Muhammad Iqbal, Pasquale, Eric Di, Nadeem-Ul-Haque, Muhammad, Ali, Hunain, Khan, Arif Iftikhar, Shaheen, Farzana, Maresca, Marc
Format: Article
Language:English
Subjects:
antimicrobial peptides
bacterial resistance
clinical strain
helicobacter pylori
human gastric explant
temporin-sha
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:is one of the most prevalent pathogens colonizing 50% of the world's population and causing gastritis and gastric cancer. Even with triple and quadruple antibiotic therapies, shows increased prevalence of resistance to conventional antibiotics and treatment failure. Due to their pore-forming activity, antimicrobial peptides (AMP) are considered as a good alternative to conventional antibiotics, particularly in the case of resistant bacteria. In this study, temporin-SHa (a frog AMP) and its analogs obtained by Gly to Ala substitutions were tested against . Results showed differences in the antibacterial activity and toxicity of the peptides in relation to the number and position of D-Ala substitution. Temporin-SHa and its analog NST1 were identified as the best molecules, both peptides being active on clinical resistant strains, killing 90-100% of bacteria in less than 1 h and showing low to no toxicity against human gastric cells and tissue. Importantly, the presence of gastric mucins did not prevent the antibacterial effect of temporin-SHa and NST1, NST1 being in addition resistant to pepsin. Taken together, our results demonstrated that temporin-SHa and its analog NST1 could be considered as potential candidates to treat , particularly in the case of resistant strains.
ISSN:2218-273X
2218-273X
DOI:10.3390/biom9100598